

WHO-PQ RECOMMENDED SUMMARY OF PRODUCT CHARACTERISTICS

This summary of product characteristics focuses on uses of the medicine covered by WHO's Prequalification Team - Medicines. The recommendations for use are based on WHO guidelines and on information from stringent regulatory authorities.
The medicine may be authorised for additional or different uses by national medicines regulatory authorities.*

*https://extranet.who.int/pqweb/sites/default/files/documents/75%20SRA%20clarification_Feb2017_newtempl.pdf

1. NAME OF THE MEDICINAL PRODUCT

[HA569 trade name][†]

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains 100 mg of nevirapine.

Excipients with known effects

Each tablet contains about 159 mg of lactose monohydrate.

For a full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

White to off-white, oval-shaped, uncoated tablet, debossed with '100' on one side and scored on the other side.

The tablet can be divided into equal doses.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

[HA569 trade name] is indicated in combination with other antiretroviral medicines for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults, adolescents and children of any age (see section 4.4).

Official guidelines (e.g., those of the WHO) on the treatment of HIV-1 infection should be consulted.

Most experience with nevirapine is in combination with nucleoside reverse transcriptase inhibitors (NRTIs). The choice of a subsequent therapy after nevirapine should be based on clinical experience and resistance testing (see section 5.1).

Nevirapine chemoprophylaxis is indicated for use in HIV-positive pregnant women (over 14 weeks of gestation) for prevention of maternal–fetal HIV transmission. The most recent official guidelines on prevention of mother-to-child transmission (PMTCT) of HIV (e.g., those issued by WHO) should be consulted to choose the appropriate regimen.

4.2 Posology and method of administration

Posology

[HA569 trade name] should be initiated by a health care provider experienced in the management of HIV infection.

If a dose is missed and it is within 8 hours of when it was due, the patient should take the missed dose as soon as possible. If a dose is missed and it is more than 8 hours of when it was due, the patient should only take the next dose at the usual time.

Children and adolescents weighing less than 25 kg

For children and adolescents weighing up to 25 kg, WHO-recommended doses are shown below; the dose is given once daily for two weeks followed by twice-daily maintenance dose. It may not be possible to use [HA569 trade name] for some of the recommended doses and alternative formulations containing smaller amount of nevirapine may be required.

[†] Trade names are not prequalified by WHO. This is the national medicines regulatory agency's responsibility.

| Weight | 'Lead-in' dose for 2 weeks ¹ | | Maintenance dose | |
|------------|---|-------------------|-----------------------------|--------------------|
| 3–5.9 kg | ½ tablet once daily | 50 mg once daily | ½ tablet twice daily | 50 mg twice daily |
| 6–9.9 kg | Use alternative formulation | 75 mg once daily | Use alternative formulation | 75 mg twice daily |
| 10–13.9 kg | 1 tablet once daily | 100 mg once daily | 1 tablet twice daily | 100 mg twice daily |
| 14–19.9 kg | Use alternative formulation | 125 mg once daily | Use alternative formulation | 125 mg twice daily |
| 20–24.9 kg | 1½ tablets once daily | 150 mg once daily | 1½ tablets once daily | 150 mg twice daily |

1. This lead-in dose for 2 weeks is recommended to avoid toxicity from high initial dose of nevirapine. However, secondary analysis from the CHAPAS-1 trial suggested that younger children have a lower risk of toxicity and consideration should be given to starting with a full dose

Children weighing 25 kg or more, adolescents and adults:

The recommended dose is 200 mg (two 100-mg tablets) daily for the first 14 days, followed by 200 mg (two 100-mg tablets) twice daily, in combination with at least two other antiretroviral medicines.

Alternative formulations such as nevirapine tablets 200 mg are more suitable for patients weighing over 25 kg.

Dose management

If a rash develops during the 14-day lead-in period with once-daily dosing then the dose of nevirapine should **not** be increased until the rash has resolved. The uncomplicated rash should be closely monitored (see section 4.4). If the rash persists longer than 28 days and the full nevirapine dose cannot be given then an alternative regimen should be considered because of the risk of developing nevirapine resistance.

If nevirapine is interrupted for longer than 7 days, it should be restarted with once-daily dosing and the dose increased after 14 days to the full, twice-daily regimen.

For adverse effects that require interruption of nevirapine therapy, see section 4.4.

Renal impairment

No dose adjustment is required for patients with creatinine clearance ≥ 20 ml/minute (see section 5.2). For patients on renal dialysis, an additional dose of [HA569 trade name] is recommended after each dialysis.

Hepatic impairment

Nevirapine should not be used in patients with severe hepatic impairment (Child-Pugh C, see section 4.3). No dose adjustment is necessary in patients with mild to moderate hepatic impairment (see sections 4.4 and 5.2).

Elderly

Nevirapine has not been specifically investigated in patients over the age of 65 years.

Method of administration

[HA569 trade name] must be administered orally, with food or between meals.

[HA569 trade name] may be dispersed in water if the child is not able to swallow the tablet. The required number of tablets should be dispersed in drinking water before administration of the dose. Each tablet should be dispersed in a minimum of 10 mL water; the maximum volume of water recommended for dispersion of the full dose is 50 mL.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Nevirapine must not be given if it has previously caused severe rash, rash accompanied by constitutional symptoms, hypersensitivity reactions, or clinical hepatitis.

Nevirapine must not be used in patients with severe hepatic impairment (Child-Pugh C) or pre-treatment aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 5 times upper limit of normal (ULN).

Nevirapine should not be given again to patients who previously developed AST or ALT > 5 times ULN during nevirapine therapy and in whom liver function abnormalities recur upon re-administration of nevirapine (see section 4.4).

Rifampicin and herbal preparations containing St John's wort (*Hypericum perforatum*) must not be used while taking nevirapine due to the risk of decreased plasma concentrations and reduced clinical effects of nevirapine (see section 4.5).

4.4 Special warnings and precautions for use

Effective antiviral therapy can substantially reduce the risk of HIV transmission. However, the risk may not be eliminated entirely. It is therefore essential to take precautions according to national and other authoritative guidelines to prevent transmission through sexual contact or blood contamination

Nevirapine should only be used with at least two other antiretroviral medicines (see section 5.1). It should not be used as the sole active antiretroviral, because monotherapy with any antiretroviral can result in the development of viral resistance.

Combination therapy with nevirapine is not a cure for HIV-1 infection; patients may continue to suffer illnesses associated with HIV-1 infection, including opportunistic infections. Continuous antiretroviral therapy is required to control HIV-1 infection and decrease HIV-related illness.

Patients should be monitored closely during the critical first 18 weeks of nevirapine therapy for **serious skin reactions** and for **severe liver disorders**. Life-threatening skin reactions (e.g., Stevens-Johnson syndrome and toxic epidermal necrolysis) and liver disorders (e.g., hepatitis or hepatic failure) can develop. The risk of hepatic events and skin reactions is greatest in the first 6 weeks of therapy. However, the risk of hepatic events persists beyond this period and monitoring should continue at frequent intervals.

Nevirapine should not be started in a patient at higher risk of hepatic adverse events unless the likely benefit outweighs the risk. The risk of hepatic adverse events is higher if the patient has detectable plasma HIV-1 RNA (i.e., ≥ 50 copies/ml), is female and the CD4 count is higher (> 250 cells/mm³ in women and > 400 cells/mm³ in men) at the start of therapy.

Patients developing signs or symptoms of hepatitis, severe skin reaction or hypersensitivity reactions must discontinue nevirapine and seek medical evaluation immediately; in some cases, hepatic injury has progressed despite discontinuing nevirapine. Rhabdomyolysis has occurred in patients with skin or liver reactions associated with nevirapine use.

Nevirapine must be permanently discontinued in case of severe hepatic injury, skin reactions or hypersensitivity reactions (characterised by rash with constitutional symptoms such as fever, arthralgia, myalgia and lymphadenopathy together with other features such as hepatitis, eosinophilia, granulocytopenia, and renal dysfunction).

The dosage must be strictly adhered to, especially in the 14-day lead-in period (see section 4.2).

Cutaneous reactions

Patients should be closely monitored for cutaneous reactions during the first 18 weeks of treatment; special care is required for infants and children because of their inability to notice and report skin reactions. Any patient who develops severe rash or a rash accompanied by constitutional symptoms such as fever, blistering, oral lesions, conjunctivitis, facial oedema, muscle or joint aches, or general malaise should discontinue nevirapine and seek medical evaluation **immediately**. In these patients nevirapine must not be restarted.

In patients with nevirapine-associated rash, liver function should be tested. Nevirapine should be discontinued permanently if liver enzymes are moderately or severely elevated (AST or ALT more than 5 times upper limit of normal).

The risk of developing serious cutaneous reactions is increased by failure to follow the initial dosing recommendations during the lead-in period or by delaying medical consultation for initial cutaneous symptoms. Exceeding the recommended dose of nevirapine might increase the frequency and seriousness of skin reactions. Women may be at higher risk of developing rash, whether receiving nevirapine or non-nevirapine containing therapy.

Patients or their guardians should be instructed that a major toxicity of nevirapine is rash. They should be advised to seek medical evaluation **without delay** if any rash occurs. They should be instructed that the dose should not be increased if any rash occurs during the two-week lead-in dosing period, until the rash resolves. The once-daily dosing regimen should not be continued beyond 28 days when an alternative treatment should be instituted.

Prednisone is **not** suitable treatment for nevirapine-induced rash.

Hepatic reactions

Severe and life-threatening hepatotoxicity, including fatal fulminant hepatitis, has occurred in patients treated with nevirapine. Close monitoring is required during the critical first 18 weeks of treatment. The risk of hepatic events is greatest in the first 6 weeks of therapy but it continues past this period and monitoring should continue at frequent intervals throughout treatment.

AST or ALT levels more than 2.5 times upper limit of normal or infection with hepatitis B or C at the start of antiretroviral therapy is associated with greater risk of hepatic adverse reactions during antiretroviral therapy in general, including nevirapine-containing regimens.

Women have a 3-fold higher risk than men for symptomatic, often rash-associated, hepatic events, patients with detectable HIV-1 RNA in plasma and higher CD4 counts at initiation of nevirapine therapy are at higher risk of hepatic events. In a retrospective review predominantly of patients with plasma HIV-1 viral load of at least 50 copies/ml, women with CD4 count > 250 cells/mm³ had a 12-fold higher risk of symptomatic hepatic adverse events compared to women with lower CD4 count (11.0% versus 0.9%). The risk was also higher in men with detectable HIV-1 RNA in plasma and CD4 count > 400 cells/mm³ (6.3% versus 1.2% for men with lower CD4 count). This increased risk for toxicity based on CD4 count thresholds has not been seen in patients with undetectable plasma viral load (i.e., < 50 copies/ml).

Healthcare providers and patients (and their guardians) should be vigilant for prodromal features of hepatitis, such as anorexia, nausea, jaundice, bilirubinuria, acholic stools, hepatomegaly or liver tenderness. Patients should be instructed to seek medical attention promptly if these occur.

If AST or ALT increase to more than 5 times upper limit of normal during treatment, nevirapine should be **stopped immediately**. If AST and ALT return to baseline values and if the patient had no signs or symptoms of hepatitis, rash, constitutional symptoms or other findings suggestive of organ dysfunction, nevirapine may be reintroduced, on a case-by-case basis, at the age-appropriate once-daily starting dose for 14 days followed by the twice-daily maintenance dose. In these cases, more frequent liver monitoring is required. If liver function abnormalities recur, nevirapine should be discontinued permanently.

In case of clinical hepatitis, characterised by anorexia, nausea, vomiting, icterus and laboratory findings, such as moderate or severe liver function test abnormalities (excluding gamma-glutamyltransferase, GGT), nevirapine must be permanently stopped. Nevirapine must not be re-administered to patients who have required permanent discontinuation for clinical hepatitis due to nevirapine.

Liver monitoring

Clinical chemistry tests, which include liver function tests, should be performed before initiating nevirapine therapy and at appropriate intervals during therapy.

Asymptomatic elevation of liver enzymes occurs frequently but is not necessarily a contraindication to using nevirapine.

Liver function should be tested every two weeks during the first 2 months of treatment, at the third month, and regularly thereafter. Liver function should be tested if the patient has signs or symptoms of hepatitis or hypersensitivity.

If AST or ALT concentration is more than 2.5 upper limit of normal before or during treatment, then liver function should be monitored more frequently during regular clinic visits. Nevirapine must not be given to patients with pre-treatment AST or ALT more than 5 times upper limit of normal until baseline AST and ALT are stabilised to less than 5 times upper limit of normal.

Liver disease

The safety and efficacy of nevirapine has not been established in patients with significant underlying liver disorders. Nevirapine is contraindicated in patients with severe hepatic impairment (Child-Pugh C). Pharmacokinetic results suggest that nevirapine should be used with caution in patients with moderate hepatic dysfunction (Child-Pugh B, see section 5.2). Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at increased risk for severe and potentially fatal hepatic adverse events. In the case of concomitant antiviral therapy for hepatitis B or C, refer also to the product information for these medicines.

Patients with liver dysfunction including chronic active hepatitis have increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored according to standard practice. If there is evidence of worsening liver disease in such patients, interruption or discontinuation of treatment must be considered.

Drug interaction with other antimicrobials

Concomitant use of nevirapine with non-nucleoside reverse transcriptase inhibitors efavirenz, delavirdine, etravirine and rilpivirine is not recommended (see section 4.5). Concomitant use of nevirapine with elvitegravir/cobicistat or with boceprevir is also not recommended (see section 4.5).

Based on pharmacokinetic data, concomitant use of rifampicin and nevirapine is not recommended. Rifampicin reduces nevirapine plasma concentration due to enzyme induction and may therefore increase the risk of treatment failure. Increasing the dose of nevirapine, however, may increase the risk of hypersensitivity reactions, including rash and hepatitis. Rifabutin should be considered instead of rifampicin. If nevirapine needs to be started during rifampicin therapy, the lead-in dose of nevirapine should be omitted. Close monitoring of adherence and of plasma HIV RNA is warranted if rifampicin and nevirapine are used concomitantly. Therapeutic drug monitoring of nevirapine, if available, should be considered.

Hormonal contraception and hormone therapy

Hormonal methods of birth control other than with depot medroxyprogesterone acetate should not be used as the sole method of contraception in women taking nevirapine because nevirapine might lower the plasma concentration of these medications. For this reason, and to reduce the risk of HIV transmission, barrier contraception (e.g., condoms) is recommended. Additionally, when postmenopausal hormone therapy is used during administration of nevirapine, its therapeutic effect should be monitored.

Lipodystrophy

Combination antiretroviral therapy has been associated with the redistribution of body fat (lipodystrophy) in HIV-infected patients. The long-term consequences of these events are currently unknown. Knowledge about the mechanism is incomplete. A higher risk of lipodystrophy has been associated with individual factors such as older age, and with drug-related factors such as longer duration of antiretroviral treatment and associated metabolic disturbances. Clinical examination should include evaluation for physical signs of fat redistribution.

Lipid disorders

Nevirapine has been associated with raised HDL-cholesterol and improved total to HDL-cholesterol ratio. However, the clinical impact of these findings is not known; the selection of antiretroviral medicines must be guided primarily by their antiviral efficacy. Measurement of fasting serum lipids and blood glucose should be considered. Lipid disorders should be managed as clinically appropriate.

Osteonecrosis

Although the aetiology of osteonecrosis is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases have been reported particularly in patients with advanced HIV-disease or with long-term exposure to combination antiretroviral therapy. Patients and their caregivers should be advised to seek medical advice in case of joint pain, joint stiffness or difficulty in movement.

Immune reactivation syndrome

In HIV-infected patients with severe immune deficiency when combination antiretroviral therapy is started, an inflammatory reaction to asymptomatic or residual opportunistic pathogens may occur and cause serious clinical conditions, or aggravation of symptoms. Typically, such reactions occur in the first few weeks or months of starting combined antiretroviral therapy. Examples of infection include cytomegalovirus (CMV) retinitis, mycobacterial infections, and *Pneumocystis jirovecii* (formerly known as *Pneumocystis carinii*) pneumonia. Autoimmune disorders such as Graves disease have also been reported; such reactions may occur many months after starting antiretroviral treatment. Any inflammatory symptoms should be evaluated and treated if necessary.

Excipients

[HA567 trade name] contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.

It is important to consider the contribution of excipients from all the medicines that the patient is taking.

4.5 Interaction with other medicinal products and other forms of interaction

Nevirapine induces CYP3A and potentially CYP2B6, with maximal induction within 2–4 weeks of initiating multiple-dose therapy. The plasma concentration of compounds using this metabolic pathway may decrease when given with nevirapine. Careful monitoring of the therapeutic effectiveness of P450-metabolised medicines is recommended when taken in combination with nevirapine.

The absorption of nevirapine is not affected by food, antacids or medicines formulated with an alkaline buffer.

The interaction data are presented as geometric mean value with 90% confidence interval (90% CI) when these data were available. ND = not determined, ↑ = increased, ↓ = decreased, ↔ = no effect

| Medicines by therapeutic area | Interaction | Recommendations concerning co-administration of nevirapine |
|--|----------------|---|
| Antimicrobials | | |
| Antiretrovirals | | |
| <i>Nucleoside reverse transcriptase inhibitors (NRTIs)</i> | | |
| Abacavir | No interaction | Abacavir and nevirapine can be given together without dose adjustments |
| Didanosine 100–150 mg twice daily | No interaction | Didanosine and nevirapine can be given together without dose adjustments |
| Emtricitabine | No interaction | Emtricitabine and nevirapine can be given together without dose adjustments |
| Lamivudine 150 mg twice daily | No interaction | Lamivudine and nevirapine can be given together without dose adjustments. |

| Medicines by therapeutic area | Interaction | Recommendations concerning co-administration of nevirapine |
|--|---|---|
| Stavudine 30/40 mg twice daily | No significant interaction | Stavudine and nevirapine can be given together without dose adjustments. |
| Tenofovir 300 mg once daily | No interaction | Tenofovir and nevirapine can be given together without dose adjustments. |
| Zidovudine 100–200 mg three times daily | No significant interaction | Zidovudine and nevirapine can be given together without dose adjustments Concomitant use of zidovudine and nevirapine, especially in children, may increase the risk of granulocytopenia |
| <i>Non-nucleoside reverse transcriptase inhibitors (NNRTI)</i> | | |
| Delavirdine | Interaction has not been studied | Concomitant administration of nevirapine with NNRTIs is not recommended (see section 5.1) |
| Efavirenz 600 mg once daily | Efavirenz AUC ↓ 0.72 (0.66–0.86) Efavirenz C _{min} ↓ 0.68 (0.65–0.81) Efavirenz C _{max} ↓ 0.88 (0.77–1.01) | Giving efavirenz and nevirapine together is not recommended because of additive toxicity and no benefit in efficacy over either NNRTI alone. |
| Etravirine | Concomitant use of etravirine with nevirapine may significantly decrease the plasma concentration of etravirine and reduce etravirine's therapeutic effect | The concomitant administration of nevirapine with NNRTIs is not recommended (see section 5.1) |
| Rilpivirine | Interaction has not been studied | The concomitant administration of nevirapine with NNRTIs is not recommended (see section 5.1) |
| <i>Protease inhibitors</i> | | |
| Atazanavir/ritonavir 300/100 mg once daily 400/100 mg once daily | <u>Atazanavir/ritonavir 300/100 mg:</u> Atazanavir/ritonavir AUC ↓ 0.58 (0.48–0.71) Atazanavir/ritonavir C _{min} ↓ 0.28 (0.20–0.40) Atazanavir/ritonavir C _{max} ↓ 0.72 (0.60–0.86) <u>Atazanavir/ritonavir 400/100 mg:</u> Atazanavir/r AUC ↓ 0.81 (0.65–1.02) Atazanavir/ritonavir C _{min} ↓ 0.41 (0.27–0.60) Atazanavir/ritonavir C _{max} ↔ 1.02 (0.85–1.24) Compared to 300/100 mg without nevirapine: Nevirapine AUC ↑ 1.25 (1.17–1.34) Nevirapine C _{min} ↑ 1.32 (1.22–1.43) Nevirapine C _{max} ↑ 1.17 (1.09–1.25) | Giving atazanavir/ritonavir and [HA569 trade name] together is not recommended. |

| Medicines by therapeutic area | Interaction | Recommendations concerning co-administration of nevirapine |
|---|---|---|
| Darunavir/ritonavir 400/100 mg twice daily | Darunavir AUC ↑ 1.24 (0.97–1.57) Darunavir C _{min} ↔ 1.02 (0.79–1.32) Darunavir C _{max} ↑ 1.40 (1.14–1.73) Nevirapine AUC ↑ 1.27 (1.12–1.44) Nevirapine C _{min} ↑ 1.47 (1.20–1.82) Nevirapine C _{max} ↑ 1.18 (1.02–1.37) | Darunavir and nevirapine can be given together without dose adjustments. |
| Fosamprenavir 1.4 g twice daily | Amprenavir AUC ↓ 0.67 (0.55–0.80) Amprenavir C _{min} ↓ 0.65 (0.49–0.85) Amprenavir C _{max} ↓ 0.75 (0.63–0.89) Nevirapine AUC ↑ 1.29 (1.19–1.40) Nevirapine C _{min} ↑ 1.34 (1.21–1.49) Nevirapine C _{max} ↑ 1.25 (1.14–1.37) | Giving fosamprenavir and nevirapine together is not recommended if fosamprenavir is not co-administered with ritonavir. |
| Fosamprenavir/ritonavir 700/100 mg twice daily | Amprenavir AUC ↔ 0.89 (0.77–1.03) Amprenavir C _{min} ↓ 0.81 (0.69–0.96) Amprenavir C _{max} ↔ 0.97 (0.85–1.10) Nevirapine AUC ↑ 1.14 (1.05–1.24) Nevirapine C _{min} ↑ 1.22 (1.10–1.35) Nevirapine C _{max} ↑ 1.13 (1.03–1.24) | Fosamprenavir/ritonavir and nevirapine can be given together without dose adjustments |
| Indinavir 800 mg three times daily | Indinavir AUC ↓ 28% Nevirapine ↔ (CYP3A4 induction) | A higher dose of indinavir or ritonavir-boosted indinavir should be considered if given with [HA569 trade name] |
| Lopinavir/ritonavir (capsules) 400/100 mg twice daily | Adults: Lopinavir AUC ↓ 0.73 (0.53–0.98) Lopinavir C _{min} ↓ 0.54 (0.28–0.74) Lopinavir C _{max} ↓ 0.81 (0.62–0.95) | An increase in the dose of lopinavir/ritonavir to 533/133 mg or 500/125 mg twice daily with food is recommended in combination with nevirapine. Dose adjustment of nevirapine is not required when given together with lopinavir. |
| Lopinavir/ritonavir (oral solution) 300/75 mg/m ² twice daily | <u>Children:</u> Lopinavir AUC ↓ 0.78 (0.56–1.09) Lopinavir C _{min} ↓ 0.45 (0.25–0.82) Lopinavir C _{max} ↓ 0.86 (0.64–1.16) | For children, increasing the dose of lopinavir/ritonavir to 300/75 mg/m ² twice daily with food should be considered when used in combination with nevirapine, particularly if reduced susceptibility to lopinavir/ritonavir is suspected. |
| Nelfinavir 750 mg three times daily | Nelfinavir AUC ↔ 1.06 (0.78–1.14) C _{min} ↔ 0.68 (0.50–1.5) C _{max} ↔ 1.06 (0.92–1.22) Nelfinavir metabolite M8: AUC ↓ 0.38 (0.30–0.47) C _{min} ↓ 0.34 (0.26–0.45) C _{max} ↓ 0.41 (0.32–0.52) Nevirapine: compared to historical controls, levels appeared to be unchanged. | Nelfinavir and nevirapine can be given together without dose adjustments. |

| Medicines by therapeutic area | Interaction | Recommendations concerning co-administration of nevirapine |
|---|---|---|
| Ritonavir 600 mg twice daily | Ritonavir AUC \leftrightarrow 0.92 (0.79–1.07) Ritonavir C _{min} \leftrightarrow 0.93 (0.76–1.14) Ritonavir C _{max} \leftrightarrow 0.93 (0.78–1.07) Nevirapine: Ritonavir does not lead to clinically relevant change in nevirapine plasma levels. | Ritonavir and nevirapine can be given together without dose adjustments. |
| Saquinavir/ritonavir | Limited data on saquinavir soft gel capsule boosted with ritonavir do not suggest clinically relevant interaction between saquinavir boosted with ritonavir and nevirapine | Saquinavir/ritonavir and nevirapine can be given together without dose adjustments. |
| Tipranavir/ritonavir 500/200 mg twice daily | No specific drug-drug interaction study has been performed. Limited data from a phase IIa study in HIV-infected patients have shown clinically non-significant 20% decrease of tipranavir C _{min} . | Tipranavir and nevirapine can be given together without dose adjustments. |
| <i>Entry inhibitors</i> | | |
| Enfuvirtide | Due to the metabolic pathway no clinically significant pharmacokinetic interaction is expected between enfuvirtide and nevirapine. | Enfuvirtide and nevirapine can be given together without dose adjustments. |
| Maraviroc 300 mg once daily | Maraviroc AUC \leftrightarrow 1.01 (0.6–1.55) Maraviroc C _{min} ND Maraviroc C _{max} \leftrightarrow 1.54 (0.94–2.52) compared to historical controls Nevirapine concentration not measured, no effect is expected. | Maraviroc and nevirapine can be given together without dose adjustments. |
| <i>Integrase inhibitors</i> | | |
| Elvitegravir/cobicistat | Interaction has not been studied. Cobicistat, a cytochrome P4503A-inhibitor significantly inhibits hepatic enzymes as well as other metabolic pathways. Therefore, co-administration would likely result in altered plasma levels of cobicistat and nevirapine | Giving [HA569 trade name] with elvitegravir in combination with cobicistat is not recommended |
| Raltegravir 400 mg twice daily | No clinical data available. Due to the metabolic pathway of raltegravir no interaction is expected. | Raltegravir and [HA569 trade name] can be given together without dose adjustments. |
| Antivirals for chronic hepatitis B and C | | |
| Adefovir | In vitro studies showed weak antagonism of nevirapine by adefovir (see section 5.1); this has not been confirmed in clinical trials and reduced efficacy is not expected. Adefovir did not influence any of the common cytochrome P450 enzymes involved in drug metabolism and is excreted renally. No clinically relevant interaction is expected. | Adefovir and [HA569 trade name] may be given together without dose adjustment |

| Medicines by therapeutic area | Interaction | Recommendations concerning co-administration of nevirapine |
|---|--|--|
| Boceprevir | Boceprevir is partly metabolised by CYP3A4/5. Giving boceprevir with medicines that induce or inhibit CYP3A4/5 could increase or decrease exposure. Plasma trough concentration of boceprevir was decreased when administered with a non-nucleoside reverse-transcriptase inhibitor with a similar metabolic pathway as nevirapine. The clinical outcome of this reduction of boceprevir trough concentrations has not been directly assessed. | Giving boceprevir and [HA569 trade name] together is not recommended |
| Daclatasvir | Interaction between nevirapine and daclatasvir has not been studied but daclatasvir concentrations are expected to fall due to induction of CYP3A4 by nevirapine. | Combination of [HA569 trade name] and daclatasvir not recommended |
| Elbasvir/grazoprevir | Interaction between elbasvir/grazoprevir and nevirapine has not been studied but elbasvir/grazoprevir concentrations are expected to fall because of induction of CYP3A4, CYP2B6 and BCRP by nevirapine; this may lead to reduced therapeutic effect | Combination of [HA569 trade name] and elbasvir/grazoprevir not recommended |
| Entecavir | Entecavir is not a substrate, inducer or an inhibitor of cytochrome P450 enzymes. Due to the metabolic pathway of entecavir, no clinically relevant drug-drug interaction is expected. | Entecavir and [HA569 trade name] may be given together without dose adjustment |
| Glecaprevir/pibrentasvir | Co-administration of nevirapine and glecaprevir/pibrentasvir has not been studied but glecaprevir/pibrentasvir concentrations may fall due to induction of CYP3A4 by nevirapine. | Combination of [HA569 trade name] and glecaprevir/pibrentasvir not recommended |
| Interferons (pegylated interferons alfa 2a and alfa 2b) | Interferons have no known effect on CYP3A4 or CYP2B6. No clinically relevant interaction is expected. | Interferons and nevirapine may be given together without dose adjustment |
| Ombitasvir/paritaprevir/ritonavir | Co-administration of nevirapine and ombitasvir/paritaprevir/ritonavir has not been studied. Plasma concentrations of ombitasvir/paritaprevir/ritonavir could decrease due to CYP3A4 induction by nevirapine; however, nevirapine exposure could increase due to inhibition by ritonavir | Combination of [HA569 trade name] and ombitasvir/paritaprevir/ritonavir is contraindicated |
| Ribavirin | In vitro studies showed weak antagonism of nevirapine by ribavirin (see section 5.1); this has not been confirmed in clinical trials and reduced efficacy is not expected. Ribavirin does not inhibit cytochrome P450 enzymes, and there is no evidence from toxicity studies that ribavirin induces liver enzymes. No clinically relevant interaction is expected. | Ribavirin and nevirapine may be given together without dose adjustment |
| Simeprevir | Interaction between nevirapine and simeprevir has not been studied but simeprevir concentrations are expected to fall due to induction of CYP3A4 by nevirapine. | Combination of [HA569 trade name] and simeprevir not recommended |

| Medicines by therapeutic area | Interaction | Recommendations concerning co-administration of nevirapine |
|---------------------------------------|---|---|
| Sofosbuvir/velpatasvir | Co-administration of nevirapine and sofosbuvir/velpatasvir has not been studied but concentrations of velpatasvir and sofosbuvir could decrease due to CYP3A4 induction by nevirapine | Combination of [HA569 trade name] and sofosbuvir/velpatasvir not recommended |
| Telaprevir | Telaprevir is metabolised in the liver by CYP3A and is a P-glycoprotein (P-gp) substrate. Other enzymes may be involved in its metabolism. Giving telaprevir and substances that induce CYP3A and P-gp (or both) may decrease telaprevir plasma concentration. No interaction study of telaprevir with nevirapine has been conducted; however, interaction studies of telaprevir with an NNRTI with a similar metabolic pathway as nevirapine found reduced levels of both. | Caution should be exercised when giving telaprevir with nevirapine. If given together with nevirapine, an adjustment in the telaprevir dose should be considered |
| Telbivudine | Telbivudine is not a substrate, inducer or inhibitor of the cytochrome P450 enzyme system. No clinically relevant interaction is expected. | Telbivudine and nevirapine may be given together without dose adjustment |
| Antibiotics | | |
| Clarithromycin 500 mg twice daily | <p>Clarithromycin AUC ↓ 0.69 (0.62–0.76) Clarithromycin C_{min} ↓ 0.44 (0.30–0.64) Clarithromycin C_{max} ↓ 0.77 (0.69–0.86)</p> <p>Metabolite 14-OH clarithromycin AUC ↑ 1.42 (1.16–1.73) Metabolite 14-OH clarithromycin C_{min} ↔ 0 (0.68–1.49) Metabolite 14-OH clarithromycin C_{max} ↑ 1.47 (1.21–1.80)</p> <p>Nevirapine AUC ↑ 1.26 Nevirapine C_{min} ↑ 1.28 Nevirapine C_{max} ↑ 1.24 compared to historical controls.</p> | <p>Clarithromycin exposure was significantly decreased, 14-OH metabolite exposure increased. Because the clarithromycin active metabolite has reduced activity against <i>Mycobacterium avium-intracellulare</i> complex overall activity against the pathogen may be altered.</p> <p>Alternatives to clarithromycin, such as azithromycin should be considered.</p> <p>Close monitoring for hepatic abnormalities is recommended</p> <p>If clarithromycin is used, at least 2-hour gap is recommended between taking [HA569 trade name] and clarithromycin</p> |
| Rifabutin 150 or 300 mg once daily | <p>Rifabutin AUC ↑ 1.17 (0.98–1.40) Rifabutin C_{min} ↔ 1.07 (0.84–1.37) Rifabutin C_{max} ↑ 1.28 (1.09–1.51)</p> <p>Metabolite 25-O-desacetyl rifabutin AUC ↑ 1.24 (0.84–1.84) Metabolite 25-O-desacetyl rifabutin C_{min} ↑ 1.22 (0.86–1.74) Metabolite 25-O-desacetyl rifabutin C_{max} ↑ 1.29 (0.98–1.68)</p> <p>A clinically not relevant increase in the apparent clearance of nevirapine (by 9%) compared to historical data was reported.</p> | <p>No significant effect on rifabutin and nevirapine pharmacokinetic parameters is seen. Rifabutin and nevirapine can be given together without dose adjustments.</p> <p>However, due to high inter-subject variability, rifabutin exposure may increase substantially in some patients, raising the risk for rifabutin toxicity.</p> <p>Combination of rifabutin and [HA569 trade name] should be used with caution.</p> |

| Medicines by therapeutic area | Interaction | Recommendations concerning co-administration of nevirapine |
|--|--|--|
| Rifampicin 600 mg once daily | Rifampicin AUC ↔ 1.11 (0.96–1.28) Rifampicin C _{min} ND Rifampicin C _{max} ↔ 1.06 (0.91–1.22) Nevirapine AUC ↓ 0.42 Nevirapine C _{min} ↓ 0.32 Nevirapine C _{max} ↓ 0.50 compared to historical controls. | Giving rifampicin and [HA569 trade name] together is not recommended. When treating tuberculosis, substituting rifabutin for rifampicin or use of an antiretroviral drug combination that omits nevirapine should be considered (see section 4.4). |
| Antifungals | | |
| Fluconazole 200 mg once daily | Fluconazole AUC ↔ 0.94 (0.88–1.01) Fluconazole C _{min} ↔ 0.93 (0.86–1.01) Fluconazole C _{max} ↔ 0.92 (0.85–0.99) Nevirapine exposure: ↑ 100% compared with historical data where nevirapine was administered alone. | Because of the risk of increased exposure to nevirapine, patients should be monitored closely for nevirapine toxicity. |
| Itraconazole 200 mg once daily | Itraconazole AUC ↓ 0.39 Itraconazole C _{min} ↓ 0.13 Itraconazole C _{max} ↓ 0.62 Nevirapine: nevirapine pharmacokinetic parameters did not change significantly. | A dose increase for itraconazole should be considered when given with [HA569 trade name]. |
| Ketoconazole 400 mg once daily | Ketoconazole AUC ↓ 0.28 (0.20–0.40) Ketoconazole C _{min} ND Ketoconazole C _{max} ↓ 0.56 (0.42–0.73) Nevirapine: plasma levels: ↑ 1.15–1.28 compared to historical controls. | Giving ketoconazole and [HA569 trade name] together is not recommended. |
| Antimalarials | | |
| Amodiaquine 600 mg once daily (with artesunate) | Amodiaquine AUC ↓ 29% Desethylamodiaquine AUC ↓ 33% | The patient treated with combination of [HA569 trade name] and amodiaquine/artesunate should be carefully monitored for efficacy and safety. Combined use may increase hepatotoxicity |
| Atovaquone, chloroquine, mefloquine, proguanil, sulfadoxine, pyrimethamine | No formal interaction study available | On theoretical basis, clinically significant interactions with nevirapine are unlikely |
| Artemisinin and its derivatives | No formal interaction study available | Nevirapine may reduce the concentration of artemisinin and its derivatives, but clinical consequences are unknown |
| Halofantrine | No formal interaction study available. Halofantrine is extensively metabolised by CYP3A and an interaction is predicted. Alteration of halofantrine metabolism could affect its plasma concentrations | [HA569 trade name] should be used cautiously with halofantrine, which has a narrow therapeutic index |

| Medicines by therapeutic area | Interaction | Recommendations concerning co-administration of nevirapine |
|--|--|--|
| Lumefantrine | Lumefantrine AUC ↑ 1.56 Lumefantrine C _{max} ↑ 1.24 | Preliminary studies suggest no increase in adverse effects of lumefantrine. Nevirapine can be given with artemether + lumefantrine without dose adjustment (see also under Artemisinin and its derivatives) |
| Quinine | Quinine AUC ↓ 0.67 Quinine C _{max} ↓ 0.64 | Nevirapine significantly lowers the concentration of quinine and can reduce its antimalarial effect |
| Anticonvulsants | | |
| Carbamazepine, phenobarbital, phenytoin | No formal interaction study available | Concentrations of nevirapine and of the anticonvulsant are expected to be reduced, leading to treatment failure; concomitant administration should be avoided unless antiretroviral (and antiepileptic) effect can be monitored closely |
| Antacids | | |
| Cimetidine | Cimetidine: no significant effect on cimetidine pharmacokinetic parameters is seen. Nevirapine: C _{min} ↑ 1.07 | Cimetidine and nevirapine can be given together without dose adjustments. |
| Anticoagulants | | |
| Warfarin | The interaction between nevirapine and warfarin is complex, with the potential for both increase and decrease in coagulation time when used concomitantly. | Close monitoring of anticoagulation activity is warranted. |
| Contraceptives | | |
| Depot medroxyprogesterone acetate 150 mg every 3 months | Medroxyprogesterone acetate AUC ↔ Medroxyprogesterone acetate C _{min} ↔ Medroxyprogesterone acetate C _{max} ↔ Nevirapine AUC ↑1.20 Nevirapine C _{max} ↑1.20 | Nevirapine did not alter the ovulation suppression effects of depot medroxyprogesterone acetate. Depot medroxyprogesterone acetate and [HA569 trade name] can be given together without dose adjustments. |
| Ethinylestradiol 35 micrograms | Ethinylestradiol AUC ↓ 0.80 (0.67–0.97) Ethinylestradiol C _{min} ND Ethinylestradiol C _{max} ↔ 0.94 (0.79–1.12) | Oral hormonal contraceptives should not be used as the sole method of contraception in women taking [HA569 trade name] (see section 4.4). Except for medroxyprogesterone acetate, appropriate doses for hormonal contraceptives (oral or other forms of application) in combination with nevirapine have not been established. |
| Norethisterone 1 mg once daily | Norethisterone AUC ↓ 0.81 (0.70–0.93) Norethisterone C _{min} ND Norethisterone C _{max} ↓ 0.84 (0.73–0.97) | |
| Drug abuse | | |
| Methadone individual patient dosing | Methadone AUC ↓ 0.40 (0.31–0.51) Methadone C _{min} ND Methadone C _{max} ↓ 0.58 (0.50–0.67) | Methadone-maintained patients beginning nevirapine therapy should be monitored for withdrawal effects and methadone dose should be adjusted accordingly. |

| Medicines by therapeutic area | Interaction | Recommendations concerning co-administration of nevirapine |
|-------------------------------|--|--|
| Herbal products | | |
| St John's wort | Serum levels of nevirapine can be reduced by concomitant use of the herbal preparation St John's wort (<i>Hypericum perforatum</i>). This is due to induction of drug metabolism enzymes, or transport proteins, or both by St. John's wort. | St. John's wort must not be given with nevirapine (see section 4.3). If a patient is already taking St John's wort, check nevirapine concentration, and if possible viral levels, and stop St John's wort if necessary. Nevirapine levels may increase on stopping St John's wort. The dose of nevirapine may need adjusting. The inducing effect may persist for at least 2 weeks after stopping St John's wort. |

Nevirapine metabolites: Studies using human liver microsomes indicated that the formation of nevirapine hydroxylated metabolites was not affected by dapsone, rifabutin, rifampicin, and trimethoprim/sulfamethoxazole. Ketoconazole and erythromycin significantly inhibited the formation of nevirapine hydroxylated metabolites.

4.6 Fertility, pregnancy and breastfeeding

Women of childbearing potential should generally not rely on hormonal contraceptives as the sole method for birth control, since nevirapine might lower the plasma concentration of hormonal contraceptives (see sections 4.4).

Pregnancy

Available data on pregnant women indicate no malformative, fetal or neonatal toxicity. No observable teratogenicity was detected in reproductive studies in rats and rabbits (see section 5.3). Caution should be exercised when prescribing nevirapine to pregnant women. Hepatotoxicity is more frequent in women with CD4 cell counts above 250 cells/mm³ with detectable HIV-1 RNA in plasma (50 or more copies per ml), and should be taken into consideration when making therapeutic decision (see section 4.4).

Breastfeeding

Nevirapine readily crosses the placenta and is found in breast milk.

Current recommendations on HIV and breastfeeding (e.g., those from the WHO) should be consulted before advising patients on this matter. Preferred options may vary depending on the local circumstances.

Fertility

In reproductive toxicology studies, evidence of impaired fertility was seen in rats.

4.7 Effects on ability to drive and use machines

There are no studies on the effects on the ability to drive and use machines.

However, patients should be advised of undesirable effects, such as fatigue, during treatment with nevirapine. Therefore, caution should be recommended and if patients experience such undesirable effect, they should avoid potentially hazardous tasks such as driving or operating machinery.

4.8 Undesirable effects

The most frequently reported adverse reactions related to nevirapine in clinical trials were rash, allergic reactions, hepatitis, abnormal liver function tests, nausea, vomiting, diarrhoea, abdominal pain, fatigue, fever, headache and myalgia.

Postmarketing experience has shown that the most serious adverse reactions are Stevens-Johnson syndrome and toxic epidermal necrolysis, serious hepatitis or hepatic failure, and hypersensitivity reactions, characterised by rash with constitutional symptoms such as fever, arthralgia, myalgia, and lymphadenopathy, plus visceral involvement, such as hepatitis, eosinophilia, granulocytopenia, and renal dysfunction. The first 18 weeks of treatment is a critical period during which close monitoring is required (see section 4.4).

The following adverse reactions related to nevirapine have been reported. The estimated frequencies are based on pooled clinical trial data for adverse reactions considered related to nevirapine treatment.

Frequency is defined using the following convention: very common ($\geq 1/10$); common ($1/100$ to $1/10$); uncommon ($1/1000$ to $1/100$); rare ($1/10\,000$ to $1/1000$); very rare ($< 1/10\,000$); not known (cannot be estimated from the available data).

Blood and lymphatic system disorders

Common: granulocytopenia (reported more frequently in children)

Uncommon: anaemia

Immune system disorders

Common: hypersensitivity (including anaphylactic reactions, angioedema and urticaria)

Uncommon: anaphylactic reactions

Rare: drug rash with eosinophilia and systemic symptoms

Nervous system disorders

Common: headache

Gastrointestinal disorders

Common: nausea, vomiting, abdominal pain, diarrhoea

Hepatobiliary disorders

Common: hepatitis (including severe and life-threatening hepatotoxicity) (1.9%)

Uncommon: jaundice

Rare: fulminant hepatitis (may be fatal)

Skin and subcutaneous tissue disorders

Very common: rash (12.5%)

Very rare: Severe cutaneous adverse reactions: Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported, angioedema, urticaria

Musculoskeletal and connective tissue disorders

Uncommon: arthralgia, myalgia

General disorders and administration site conditions

Common: fever, fatigue

Investigations

Common: liver function test abnormal (alanine aminotransferase increased; transaminases increased; aspartate aminotransferase increased; gamma-glutamyltransferase increased; hepatic enzyme increased; hypertransaminasaemia)

Uncommon: blood phosphorus decreased, blood pressure increased

Description of selected adverse reactions

Combination antiretroviral therapy has been associated with redistribution of body fat (lipodystrophy) in HIV patients including the loss of peripheral and facial subcutaneous fat, increased intra-abdominal and visceral fat, breast hypertrophy and dorsocervical fat accumulation (buffalo hump).

Combination antiretroviral therapy has been associated with metabolic abnormalities such as hypertriglyceridaemia, hypercholesterolaemia, insulin resistance, hyperglycaemia and hyperlactataemia (see section 4.4).

The following adverse reactions have also been reported when nevirapine has been used in combination with other antiretroviral agents: pancreatitis, peripheral neuropathy and thrombocytopaenia. These adverse reactions are commonly associated with other antiretroviral agents and may be expected when nevirapine is used in combination with other agents; however, it is unlikely that these adverse reactions are due to nevirapine treatment. Hepatic-renal failure syndromes have been reported rarely.

In HIV-infected patients with severe immune deficiency at the time of starting combination antiretroviral therapy, an inflammatory reaction to asymptomatic or residual opportunistic infections may arise (see section 4.4). Autoimmune disorders (such as Graves' disease) have also been reported; however, the reported time to onset is more variable and these events can occur many months after starting treatment (see section 4.4).

Cases of osteonecrosis have been reported, particularly in patients with risk factors, advanced HIV disease or long-term exposure to combination antiretroviral therapy. The frequency of this is unknown (see section 4.4).

Skin and subcutaneous tissues

The most common clinical toxicity of nevirapine is rash, with nevirapine-attributable rash occurring in 12.5% of patients in combination regimens in controlled studies.

Rashes are usually mild to moderate, maculopapular erythematous cutaneous eruptions, with or without pruritus, located on the trunk, face and extremities. Hypersensitivity (anaphylactic reaction, angioedema and urticaria) have been reported. Rashes occur alone or in the context of drug rash with eosinophilia and systemic symptoms, characterised by rash with constitutional symptoms such as fever, arthralgia, myalgia and lymphadenopathy, plus visceral involvement, such as hepatitis, eosinophilia, granulocytopenia, and renal dysfunction.

Severe and life-threatening skin reactions have occurred in patients treated with nevirapine, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Fatal cases of Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug rash with eosinophilia and systemic symptoms have been reported. The majority of severe rashes occurred within the first 6 weeks of treatment and some required hospitalisation, with one patient requiring surgical intervention (see section 4.4).

Hepato-biliary disorders

The most frequently observed laboratory test abnormalities are elevations in liver function tests, including ALT, AST, gamma-glutamyltransferase (GGT), total bilirubin and alkaline phosphatase. Asymptomatic elevations of GGT levels are the most frequent. Cases of jaundice have been reported. Cases of hepatitis (severe and life-threatening hepatotoxicity, including fatal fulminant hepatitis) have been reported in patients treated with nevirapine. The best predictor of a serious hepatic event was elevated baseline liver function tests. The first 18 weeks of treatment is a critical period which requires close monitoring (see section 4.4).

Paediatric population

Based on clinical study experience of 361 paediatric patients, the majority of whom received combination treatment with zidovudine or didanosine, or both, the most frequently reported adverse events related to nevirapine were similar to those in adults. Granulocytopenia was more frequent in children. In an open-label clinical study (ACTG 180) granulocytopenia assessed as medicine-related occurred in 5/37 (13.5 %) of patients. In a double-blind, placebo-controlled study, the frequency of serious medicine-related granulocytopenia was 5/305 (1.6 %).

Isolated cases of Stevens-Johnson syndrome or Stevens-Johnson with transition to toxic epidermal necrolysis have been reported in children.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Health care providers are asked to report any suspected adverse reactions to the marketing authorisation holder, or, if available, via the national reporting system.

4.9 Overdose

There is no antidote for nevirapine overdosage. Cases of nevirapine overdose at doses ranging from 800 mg to 6000 mg per day for up to 15 days have been reported. Patients have experienced oedema, erythema nodosum, fatigue, fever, headache, insomnia, nausea, pulmonary infiltrates, rash, vertigo, vomiting, increase in transaminases and weight decrease. All of these effects subsided following discontinuation of nevirapine.

Children

One case of massive accidental overdose in a new born was reported. The ingested dose was 40 times the recommended dose of 2 mg/kg/day. Mild isolated neutropenia and hyperlactataemia was found, which resolved spontaneously within one week without any clinical complications. One year later, the child's development remained normal.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: antivirals for systemic use, non-nucleoside reverse transcriptase inhibitors (NNRTI), ATC code J05AG01.

Mechanism of Action

Nevirapine is a non-competitive inhibitor of the HIV-1 reverse transcriptase, but it does not have a biologically significant inhibitory effect on HIV-2 reverse transcriptase or on eukaryotic DNA polymerases α , β , γ , or δ .

Clinical efficacy

Clinical studies on nevirapine have demonstrated significant decrease in plasma HIV RNA and increases in CD4 cell count when used in combination with other nucleoside analogues, or a protease inhibitor, or both.

In a multicentre open-label randomised trial in patients not previously treated with antiretrovirals, 220 patients were assigned to receive nevirapine 400 mg once daily, 387 to nevirapine 200 mg twice daily, 400 to efavirenz once daily and 209 to both efavirenz and nevirapine, all combined with lamivudine and stavudine, for 48 weeks. Treatment failure (the primary endpoint) was reached by 43.7% patients receiving nevirapine once daily, 43.7% receiving nevirapine twice daily, 37.8% receiving efavirenz and 53.1% receiving both drugs. Antiretroviral therapies with nevirapine or efavirenz were considered to have similar efficacy, but the adverse-effects of regimens containing the two were different.

A multicentre open-label randomised trial in patients taking two nucleoside reverse transcriptase inhibitors and at least one protease inhibitor, and in whom viral suppression had been achieved, switched patients from the protease inhibitor to nevirapine (155 patients), efavirenz (156) or abacavir (149). The likelihood of reaching the endpoint (death, progression to AIDS, or an increase in viral RNA level above 200 copies/ml) at 12 months was 10% in the nevirapine group, 6% in the efavirenz group and 13% in the abacavir group. Fewer patients in the abacavir group (6%) than in the nevirapine group (17%) or the efavirenz group (17%) discontinued the study medication because of adverse events.

Drug resistance

The most common resistance mutations selected for by nevirapine are Y181C, K103N and G190A. All these mutations cause high-level resistance to nevirapine. Patients failing nevirapine-containing antiretroviral therapy can also develop cross-resistance to efavirenz and delavirdine (<http://hivdb.stanford.edu>). Similarly,

patients failing therapy which includes efavirenz or delavirdine will usually have a virus cross-resistant to nevirapine. If failing therapy is continued, further resistance mutations will accumulate.

High-level resistance to nevirapine can occur after a single dose when used alone, as has been demonstrated by the high prevalence of resistance mutations after using nevirapine for preventing mother-to-child transmission. When effective nevirapine-containing antiretroviral therapy is discontinued, the prolonged persistence of nevirapine in the body may lead to significant nevirapine resistance. This may compromise the effectiveness of NNRTI therapy used in the future.

Perinatal Transmission

A study evaluated the efficacy of nevirapine to prevent transmission of HIV-1 infection from mother to baby. Mothers received only study antiretroviral therapy during these trials. Mother-infant pairs were randomised to receive oral nevirapine (mother: nevirapine 200 mg at the onset of labour; infant: nevirapine 2 mg/kg within 72 hours of birth), or an ultra-short oral zidovudine regimen (mother: zidovudine 600 mg at the onset of labour and 300 mg every 3 hours until delivery; infant zidovudine 4 mg/kg twice daily for 7 days). The HIV-1 infant infection rate at 14–16 weeks was 13.1% (n = 310) in the nevirapine group, versus 25.1% (n = 308 in the ultra-short zidovudine group (p = 0.00063).

A study in 123 women who had received single-dose nevirapine for preventing mother-to-child transmission and who were then treated with nevirapine combined with other antiretroviral drugs indicated that single-dose nevirapine alone reduces the efficacy of subsequent use of nevirapine as part of combination antiretroviral therapy.

Paediatric population

Results of a 48-week analysis of a South African study confirmed that the 4/7 mg/kg and 150 mg/m² doses of nevirapine dose groups were well tolerated and effective in treating antiretroviral-naïve paediatric patients. A marked improvement in the CD4 cell percent was observed after 48 weeks for both dose groups. Also, both dosing regimens were effective in reducing the viral load. In this 48-week study there were no unexpected safety findings in either dosing group.

5.2 Pharmacokinetic properties

No pharmacokinetic data are available for [HA569 trade name]. A bioequivalence study was conducted with [HA570 trade name] which contains 200 mg nevirapine and is essentially the same as [HA569 trade name] in qualitative terms and with respect to the ratio of active and other ingredients.

The absorption characteristics of [HA570 trade name] have been determined after administration of one nevirapine 200 mg tablet in healthy volunteers in the fasting state as follows:

| Pharmacokinetic variable | Mean value* (±standard deviation) |
|---|--------------------------------------|
| | Nevirapine |
| Maximum concentration (C _{max}) | 2.47 ± 0.71 µg/mL |
| Area under the curve (AUC _{0-72h}), a measure of the extent of absorption | 115.12 ± 25.58 µg·h/mL |
| Time to attain maximum concentration (T _{max}) | 7.5 ± 8.4 hours |

*arithmetic mean

Pharmacokinetics of nevirapine

| Absorption | |
|----------------------|------|
| Oral bioavailability | >90% |
| Distribution | |

| | |
|---------------------------------------|--|
| Volume of distribution (mean) | 1.2 L/kg |
| Plasma proteinbinding <i>in vitro</i> | 60% |
| Metabolism | |
| | Cytochrome P450 isozymes CYP3A and CYP2B6, and glucuronidation. Autoinduction resulting in decreased plasma half-life after 2-4 weeks of dosing Three major metabolites: 2-hydroxy-nevirapine glucuronide, 3-hydroxy-nevirapine glucuronide and 12-hydroxy-nevirapine glucuronide |
| Active metabolite(s) | None |
| Elimination | |
| Elimination half life | 45 h after single dose and 25-30 hours after multiple doses (200-400 mg) |
| Mean systemic clearance (Cl/F) | 1.6 L/h/kg |
| % of dose excreted in urine | > 80% (<5% excreted unchanged) |
| % of dose excreted in faeces | 10% |
| Pharmacokinetic linearity | Linear pharmacokinetics |
| Metabolizing enzymes | CYP3A, CYP2B6, UGT |

Special populations

Renal dysfunction: Renal impairment (mild, moderate and severe) does not significantly change the pharmacokinetics of nevirapine. The dose of nevirapine does not need to be adjusted in patients with creatinine clearance ≥ 20 ml/minute. However, in subjects with end-stage renal disease on dialysis, nevirapine AUC was reduced. There is also accumulation of nevirapine hydroxy-metabolites in plasma. An additional 200-mg dose of nevirapine following each dialysis treatment could help offset the effects of dialysis on nevirapine clearance.

Hepatic dysfunction: The disposition of nevirapine and the five oxidative metabolites is not altered in patients with mild to severe liver fibrosis. However, in a few patients with hepatic fibrosis nevirapine trough concentration may be 2-fold higher than the usual mean trough concentration. Patients with hepatic impairment should be monitored carefully for drug-induced toxicity.

5.3 Preclinical safety data

Preclinical data reveal no special hazard for humans other than those observed in clinical studies based on conventional studies of safety, pharmacology, repeated-dose toxicity, and genotoxicity. In reproductive toxicology studies, evidence of impaired fertility was seen in rats. In carcinogenicity studies, nevirapine induces hepatic tumours in rats and mice. These findings are most likely related to nevirapine being a strong inducer of liver enzymes, and not due to a genotoxic mode of action.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Lactose monohydrate
Microcrystalline cellulose
Sodium starch glycolate
Colloidal silicon dioxide
Povidone
Magnesium stearate

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

60 months

6.4 Special precautions for storage

Do not store above 30°C.

6.5 Nature and contents of container

HDPE bottle
Round, opaque, white-coloured HDPE bottle, with a polypropylene child-resistant cap.
Pack sizes: 30, 60 and 90 tablets.

Blisters
PVC/PVDC-Al blisters. Pack size: 10 tablets per blister card. 3 or 6 cards in a carton.

6.6 Instructions for use and handling and disposal

No special requirements.
Any unused product or waste material should be disposed of in accordance with local requirements.

7. SUPPLIER

Micro Labs Limited
31, Race Course Road
Bangalore - 560001, Karnataka, India
Tel: + 91 80 2237 0451 to 2237 0456
Fax: + 91 80 2237 0463
Email: exp@microlabs.in

8. WHO REFERENCE NUMBER (WHO Prequalification Programme)

HA569

9. DATE OF PREQUALIFICATION

19 February 2014

10. DATE OF REVISION OF THE TEXT

February 2021

References

General Reference

The major source for the information in this SmPC is the European SmPC for Viramune available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000183/WC500051481.pdf (accessed on 21 May 2019)

For further information, the following sources have also been used.

Consolidated Guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach - second edition 2016.
<http://www.who.int/hiv/pub/arv/arv-2016/en/>

World Health Organisation. Interim Guidelines: Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV. Supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. December 2018
<https://apps.who.int/iris/bitstream/handle/10665/277395/WHO-CDS-HIV-18.51-eng.pdf?ua=1> (accessed on 22 May 2019)

4.2 Posology

World Health Organization. Antiretroviral therapy for HIV infection in infants and children: towards universal access 2010 revision. Geneva: WHO; 2010

WHO: Rapid advice—Use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants 2009, available at: <http://www.who.int/hiv/pub/mtct/advice/en/>

4.5 Drug interactions

Soyinka JO, Onyeji CO, Omoruyi SJ, et al. Effects of concurrent administration of nevirapine on the disposition of quinine in healthy volunteers. J Pharm Pharmacol 2009; 61: 439–43

Kredo T, Van der Walt JS, Mauff K, et al. Nevirapine increases lumefantrine exposure in HIV-infected subjects [abstract 603]. 17th Conference on Retroviruses and Opportunistic Infections; 2010 Feb 16-18; San Francisco, California

L'homme RFA, Dijkema T, van der Ven AJAM, Burger DM. Enzyme inducers reduce elimination half-life after a single dose of nevirapine in healthy women. J Acquir Immune Defic Syndr 2006; 43: 193–6

5.1 Clinical efficacy

French M, Amin J, Roth N et al. Randomized, open-Label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: The OzCombo 2 study. HIV Clin Trials 2002; 3: 177

van Leth F, Phanuphak P, Ruxrungtham K et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2 NN Study. Lancet 2004; 363: 1253–63

Martinez E, Arnaiz JA, Podzamczar D, et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 2003; 349: 1036–46

Detailed information on this medicine is available on the World Health Organization (WHO) website:
<https://extranet.who.int/pqweb/medicines>